HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and supplying nucleic acid delivery technology for partners in biotech and pharma, today announced that its associate company Altamira Medica ("Medica") received a notice of allowance from the Japan Patent Office for Medica's patent application covering its Bentrio® nasal spray. ...

Conformity with stringent new EU regulations for medical devices confirmed Allows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countries Major milestone in international growth strategy HAMILTON, BERMUDA / ACCESS Newswire / November 20, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and supplying nucleic acid delivery technology for partners in biotech and pharma, today announced that ...